Search research articles
Contact Us
Filters
Showing results (51-60 of 137) with videos related to
Page
of 14
Sort By:
Cancer
|
September 7, 2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature
Brian H Kushner, Shakeel Modak, Kim Kramer, et al.
Journal of Hematology & Oncology
|
November 27, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial
Brian H Kushner, Shakeel Modak, Audrey Mauguen, et al.
JAMA Oncology
|
October 17, 2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial
Brian H Kushner, Irene Y Cheung, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 6, 2017
Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy
Thomas H Beckham, Dana L Casey, Michael P LaQuaglia, et al.
Pediatric Blood & Cancer
|
June 24, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma
Wei Wei, Maggie Eidson Fader, Brian H Kushner, et al.
Pediatric Blood & Cancer
|
January 28, 2021
Mandibular metastases in neuroblastoma: Outcomes and dental sequelae
Annu Singh, Shakeel Modak, Armand K Solano, et al.
Oncoimmunology
|
November 18, 2017
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival
Irene Y Cheung, Brian H Kushner, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 31, 2016
Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma
Dana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.
Pediatric Blood & Cancer
|
February 23, 2018
Dose-escalation is needed for gross disease in high-risk neuroblastoma
Dana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.
Health Physics
|
December 14, 2006
Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma
Lawrence T Dauer, Jean St Germain, Matthew J Williamson, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 137) with videos related to
Sort By:
Page
of 14
Cancer
|
September 7, 2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature
Brian H Kushner, Shakeel Modak, Kim Kramer, et al.
Journal of Hematology & Oncology
|
November 27, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial
Brian H Kushner, Shakeel Modak, Audrey Mauguen, et al.
JAMA Oncology
|
October 17, 2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial
Brian H Kushner, Irene Y Cheung, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 6, 2017
Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy
Thomas H Beckham, Dana L Casey, Michael P LaQuaglia, et al.
Pediatric Blood & Cancer
|
June 24, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma
Wei Wei, Maggie Eidson Fader, Brian H Kushner, et al.
Pediatric Blood & Cancer
|
January 28, 2021
Mandibular metastases in neuroblastoma: Outcomes and dental sequelae
Annu Singh, Shakeel Modak, Armand K Solano, et al.
Oncoimmunology
|
November 18, 2017
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival
Irene Y Cheung, Brian H Kushner, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 31, 2016
Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma
Dana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.
Pediatric Blood & Cancer
|
February 23, 2018
Dose-escalation is needed for gross disease in high-risk neuroblastoma
Dana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.
Health Physics
|
December 14, 2006
Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma
Lawrence T Dauer, Jean St Germain, Matthew J Williamson, et al.
Page
of 14